Penumbra (PEN) Free Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.41% |
| Dec 31, 2025 | -3.52% |
| Sep 30, 2025 | 192.04% |
| Jun 30, 2025 | -17.28% |
| Mar 31, 2025 | -45.40% |
| Dec 31, 2024 | 27.46% |
| Sep 30, 2024 | 182.25% |
| Jun 30, 2024 | -44.33% |
| Mar 31, 2024 | -30.39% |
| Dec 31, 2023 | 124.87% |
| Sep 30, 2023 | 6.24% |
| Jun 30, 2023 | 111.42% |
| Mar 31, 2023 | 515.06% |
| Dec 31, 2022 | 88.45% |
| Sep 30, 2022 | 56.24% |
| Jun 30, 2022 | -364.64% |
| Mar 31, 2022 | 63.02% |
| Dec 31, 2021 | -175.67% |
| Sep 30, 2021 | 1,106.75% |
| Jun 30, 2021 | 79.69% |
| Mar 31, 2021 | -738.93% |
| Dec 31, 2020 | -116.74% |
| Sep 30, 2020 | 141.48% |
| Jun 30, 2020 | -76.99% |
| Mar 31, 2020 | -435.16% |
| Dec 31, 2019 | -76.54% |
| Sep 30, 2019 | 1,285.95% |
| Jun 30, 2019 | 150.31% |
| Mar 31, 2019 | -137.20% |
| Dec 31, 2018 | -22.77% |
| Sep 30, 2018 | 1,872.70% |
| Jun 30, 2018 | -105.59% |
| Mar 31, 2018 | 254.97% |
| Dec 31, 2017 | -171.23% |
| Sep 30, 2017 | 712.70% |
| Jun 30, 2017 | -52.00% |
| Mar 31, 2017 | 78.82% |
| Dec 31, 2016 | -300.98% |
| Sep 30, 2016 | 127.04% |
| Jun 30, 2016 | -172.44% |
| Mar 31, 2016 | 78.14% |
| Dec 31, 2015 | -428.59% |
| Sep 30, 2015 | 49.52% |
| Jun 30, 2015 | -63.34% |
| Mar 31, 2015 | 63.62% |